271 related articles for article (PubMed ID: 16149870)
1. CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment.
Blennow K
Expert Rev Mol Diagn; 2005 Sep; 5(5):661-72. PubMed ID: 16149870
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid biomarkers for Alzheimer's disease.
Blennow K; Zetterberg H
J Alzheimers Dis; 2009; 18(2):413-7. PubMed ID: 19661632
[TBL] [Abstract][Full Text] [Related]
3. CSF biomarkers for mild cognitive impairment.
Blennow K
J Intern Med; 2004 Sep; 256(3):224-34. PubMed ID: 15324365
[TBL] [Abstract][Full Text] [Related]
4. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.
Andreasen N; Blennow K
Clin Neurol Neurosurg; 2005 Apr; 107(3):165-73. PubMed ID: 15823670
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal stability of CSF biomarkers in Alzheimer's disease.
Blennow K; Zetterberg H; Minthon L; Lannfelt L; Strid S; Annas P; Basun H; Andreasen N
Neurosci Lett; 2007 May; 419(1):18-22. PubMed ID: 17482358
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
Formichi P; Battisti C; Radi E; Federico A
J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
[TBL] [Abstract][Full Text] [Related]
7. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
Parnetti L; Lanari A; Silvestrelli G; Saggese E; Reboldi P
Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
[TBL] [Abstract][Full Text] [Related]
8. [Biomarkers for early diagnosis of Alzheimer's disease: current update and future directions].
Malaplate-Armand C; Desbene C; Pillot T; Olivier JL
Rev Neurol (Paris); 2009; 165(6-7):511-20. PubMed ID: 19041993
[TBL] [Abstract][Full Text] [Related]
9. Neurochemical dementia diagnostics: State of the art and research perspectives.
Lewczuk P; Wiltfang J
Proteomics; 2008 Mar; 8(6):1292-301. PubMed ID: 18271068
[TBL] [Abstract][Full Text] [Related]
10. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42).
Kaiser E; Schönknecht P; Thomann PA; Hunt A; Schröder J
Neurosci Lett; 2007 May; 417(2):193-5. PubMed ID: 17408854
[TBL] [Abstract][Full Text] [Related]
11. [Alzheimer's disease as brain amyloidosis: diagnosis using cerebrospinal fluid abeta and tau].
Shoji M
Rinsho Byori; 2006 May; 54(5):503-8. PubMed ID: 16789421
[TBL] [Abstract][Full Text] [Related]
12. A mathematical model of the impact of novel treatments on the A beta burden in the Alzheimer's brain, CSF and plasma.
Craft DL; Wein LM; Selkoe DJ
Bull Math Biol; 2002 Sep; 64(5):1011-31. PubMed ID: 12391865
[TBL] [Abstract][Full Text] [Related]
13. Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful?
Borroni B; Di Luca M; Padovani A
Eur J Pharmacol; 2006 Sep; 545(1):73-80. PubMed ID: 16831417
[TBL] [Abstract][Full Text] [Related]
14. [Biochemical markers for Alzheimer disease].
Czarna JM; Waldemar G; Heegaard NH
Ugeskr Laeger; 2006 Mar; 168(10):1010-4. PubMed ID: 16522291
[TBL] [Abstract][Full Text] [Related]
15. [CSF biomarkers: proteomics investigations and clinical applications in neurodegenerative disorders].
Gabelle A; Roche S; Lehmann S
Rev Neurol (Paris); 2009 Mar; 165(3):213-22. PubMed ID: 18808768
[TBL] [Abstract][Full Text] [Related]
16. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
[TBL] [Abstract][Full Text] [Related]
17. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
19. Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease.
Skogseth R; Mulugeta E; Jones E; Ballard C; Rongve A; Nore S; Alves G; Aarsland D
Dement Geriatr Cogn Disord; 2008; 25(6):559-63. PubMed ID: 18536520
[TBL] [Abstract][Full Text] [Related]
20. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
